Proton pump inhibitors as a treatment method for type II diabetes

Medical Hypotheses

Volumn 73, Issue 1, 2009, Pages 29-32

  Mefford, Ivan N ^a   Wade, Ekpedeme U ^a  

^a Fort Bend Premier Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ESOMEPRAZOLE; GASTRIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LANSOPRAZOLE; METFORMIN; OMEPRAZOLE; PANTOPRAZOLE; PIOGLITAZONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROSIGLITAZONE; SITAGLIPTAN; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; GASTRIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HUMANS; PREVALENCE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 64749093211     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.02.010     Document Type: Article

References (24)

1. State-specific incidence of diabetes among adults participating states, 1995-1997 and 2005-2007. JAMA, 2008;300(24):2847-9.
2. Diabetes atlas. 2nd ed. Executive summary; 2003.
3. Muscelli E., Mari A., Casolaro A., et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57 5 (2008) 1340-1348
4. Bell D.S.H. Current status of diabetes treatment. S Med J 95 1 (2002) 24-29
5. Suarez-Pinzon W.L., Yan Y., and Rabinovitch A. Combination therapy with gastrin and glucagon-like peptide-1 (GLP-1) restores pancreatic insulin content and corrects hyperglycemia after diabetes onset in NOD mice. Can J Diab 28 (2004) 257
6. Rooman I., Lardon J., and Bouwens L. Gastrin stimulates B-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas. Diabetes 51 (2002) 686-690
7. Cowey S.L., Quast M., Belalcazar L.M., et al. Abdominal obesity, insulin resistance and colon carcinogenesis are in creased in mutant mice lacking gastrin gene expression. Cancer 103 12 (2005) 2643-2653
8. Schubert M.L., and Makhlouf G.M. Neural, hormonal and paracrine regulation of gastrin and acid secretion. Yale J Biol Med 65 (1992) 553-560
9. Parkinson J. A case of pernicious anaemia terminating in acute diabetes. Lancet II (1910) 416-418
10. Rehfeld J.F. Disturbed islet-cell function related to endogenous gastrin release. J Clin Invest 58 (1976) 41-49
11. Rehfeld J.F., and Stadil F. The effect of gastrin on basal-and glucose-stimulated insulin secretion in man. J Clin Invest 52 (1973) 1415-1426
12. Rehfeld J.F., Stadil F., Baden H., and Fischermann K. The enteral insulin-stimulation after Whipple's operation. Diabetologia 11 (1975) 207-210
13. Meier J.J., Butler A.E., Galasso R., Rizza R.A., and Butler P.C. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia 49 (2006) 2689-2696
14. Yoshihisa U., Susumu I., Yasuyuki M., et al. Effect of serum gastrin concentration on insulin resistance. Digest Absorp 28 2 (2006) 42-45
15. Creutzfeldt W. The consequences of hypergastrinemia. Yale J Biol Med 67 (1994) 709-723
16. Gurden G., Boyacioglu S., Gul C., et al. Impact of helicobacter pylori infection on serum gastrin in haemodialysis patients. Nephrol Dial Transplant 14 (1999) 2688-2691
17. Peach H.G., and Barnett N.E. Helicobacter pylori infection and fasting plasma glucose concentration. J Clin Pathol 54 (2001) 466-469
18. Hu Y.-M., Mei Q., Xu X.-H., Hu X.-P., Hu N.-Z., and Xu J.-M. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol 12 29 (2006) 4750-4753
19. Ligumsky M., Lysy J., Siguencia G., and Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 33 1 (2001) 32-35
20. Cadiot G., Vissuzaine C., Pospai D., Ruszniewski P., Potet F., and Mignon M. Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Gastroenterol Clin Biol 19 10 (1995) 811-817
21. Koop H., Klein M., and Arnold R. Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 4 (1990) 131-138
22. Vanderhoff B.T., and Tahboub R.M. Proton pump inhibitors: an update. Am Fam Physician 66 2 (2002) 273-280
23. Sanders S.W., Tolman K.G., Greski P.A., Jennings D.E., Hoyos P.A., and Page J.G. The effects of lansoprazole, a new H+, K+-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 6 (1992) 359-372
24. Banerjee S., Ardill J.E.S., Beattie A.D., and McColl K.E.L. Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria. Aliment Pharmacol Ther 9 (1995) 507-512